DOCSLIB.ORG

Helicobacter Pylori: a Brief History of a Still Lacking Vaccine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Helicobacter Pylori: a Brief History of a Still Lacking Vaccine Diseases 2014, 2, 187-208; doi:10.3390/diseases2020187 OPEN ACCESS diseases ISSN 2079-9721 www.mdpi.com/journal/diseases/ Review Helicobacter pylori: A Brief History of a Still Lacking Vaccine Paolo Ruggiero * and Stefano Censini Novartis Vaccines, Research Center, Via Fiorentina 1, I-53100 Siena, Italy; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-0577-539-320; Fax: +39-0577-539-314. Received: 16 January 2014; in revised form: 29 April 2014 / Accepted: 19 May 2014 / Published: 16 June 2014 Abstract: Helicobacter pylori colonizes the gastric mucosa of more than half of the human population worldwide. Soon after its discovery, the causative relationships between H. pylori infection and chronic atrophic gastritis, peptic ulcer and gastric mucosa-associated lymphoid tissue lymphoma were evidenced. Then, a significantly increased risk of developing gastric cancer was found to be associated with H. pylori infection. The efficacy of the treatment for H. pylori, based on a proton pump inhibitor plus antibiotics, has dropped below 80%, mainly due to antibiotic resistance. Vaccination would overcome antibiotic resistance and would lead to the eradication of this pathogen; however, in spite of almost twenty-five years of investigation on H. pylori vaccine candidates and good protective results obtained in animal models, no vaccine is currently licensed. This review focuses on the studies on the efficacy of those H. pylori vaccine candidates that underwent clinical trials. Efficacy trials have given unsatisfactory results, so far, with bacterial colonization remaining unaffected by vaccination. However, a vaccine able to counteract H. pylori-induced diseases, such as gastric cancer, even without providing sterilizing immunity, could be considered valuable. Keywords: Helicobacter pylori; vaccine; animal models; efficacy Diseases 2014, 2 188 1. Introduction The presence of bacteria in mammalian stomach has been reported since the late 19th century; nevertheless, only at the beginning of the 1980s did Barry Marshall and Robin Warren describe a bacterium isolated and cultured from human gastric biopsies [1], initially classified as Campylobacter pylori and, then, as Helicobacter pylori [2]. Soon after the discovery of H. pylori, its causative relationship with gastritis and peptic ulcer in humans was proven [3]. In 2005, Marshall and Warren received the Nobel Prize in Physiology or Medicine for their revolutionary discovery. H. pylori is a curved or spiral-shaped, flagellated, microaerophilic, Gram-negative bacillus. It colonizes the gastric mucosa of more than 50% of human population, with much higher prevalence in developing than in developed countries [4,5], most probably as a consequence of different hygiene and living conditions. H. pylori is generally acquired during childhood, within the family [6,7]. The colonization is long-lasting, commonly for the entire life. The most likely route of transmission is oral-oral and/or fecal-oral [8]. Moreover, since H. pylori was detected both in water and milk [9–11], these could represent possible further routes of transmission, although to date, there is not a formal demonstration of this hypothesis. The H. pylori colonization remains asymptomatic in the majority of the subjects, but a subset of the H. pylori-infected population develops chronic gastritis, peptic ulcer or gastric mucosa-associated lymphoid tissue (MALT) lymphoma [3,12,13]. Moreover, H. pylori colonization was found associated with an increased risk of gastric carcinogenesis [14,15]: thus, the WHO has included H. pylori among the Category 1 carcinogens [16]. H. pylori is the only bacterium that has been clearly associated with the development of cancer to date [17]. In particular, H. pylori CagA (the product of cytotoxin-associated Gene A, cagA) has been shown to trigger many cancer-related signaling pathways in vitro and in vivo, as will be described more in detail below. Several studies have tried to define the possible association of H. pylori with other carcinomas: significant association was found with squamous cell laryngeal cancer and squamous cell cancer of the upper aerodigestive tract (excluding the esophagus), while for other carcinomas, to date, the results are controversial or the size of the studies too small to reach definitive conclusions [18]. H. pylori may also induce or worsen gastric autoimmunity through the activation of cytolytic CD4+ Th1 cells specific for H. pylori peptides cross-reactive with human H+, K+-ATPase: these cells infiltrate the gastric mucosa and may contribute to developing gastric atrophy [19,20]. The diagnosis of H. pylori infection in symptomatic subjects is generally followed by eradication therapy. The eradication causes the regression of H. pylori-induced peptic ulcer and MALT lymphoma [21] and may represent a tool for the reduction of gastric cancer incidence in populations at risk [22]. Current therapies against H. pylori are based on the use of one proton pump inhibitor plus two or more antibiotics for one–two weeks, with various approaches that also vary according to the geographic area [23–25]. Antibiotic-based therapy presents some drawbacks. If eradication is done at late stages of colonization, when pre-malignant lesions are already present, it could be too late for reverting the mechanisms of carcinogenesis already triggered [26]. The efficacy of the treatments has dropped even below 80% in some cases [27], mainly due to the increase of antibiotic resistance; thus, modifications in the combination and in the sequence of drug administration are continuously under Diseases 2014, 2 189 investigation [23,28]. Moreover, after treatment, recurrence and/or reinfection can occur [29], especially in developing countries [30]. Vaccination would represent a valid and cost-effective [31,32] alternative approach to overcome the problems with the antibiotic-based therapy. 2. Vaccination against H. pylori in Animal Models Several animal models of infection with H. pylori have been described [33]; among them, the mouse model was the most exploited. These animal models allowed the production of a large body of data demonstrating the feasibility and the efficacy of vaccination against H. pylori [34,35]. Since H. pylori colonization occurs at the mucosal level, particular emphasis has been given to oral immunization, although other mucosal routes of immunization [36], as well as the parenteral route [35] or prime-boost regimens, have been considered [37–39]. Mucosal immunization requires the use of strong mucosal adjuvants, as proteins are poor immunogens when administered mucosally. Some of the strongest mucosal adjuvants presently known are bacterial toxins, such as cholera toxin (CT) and the E. coli heat-labile enterotoxin (LT), which, however, induce severe diarrhea in humans, seriously limiting their use; thus, non-toxic mutants of these molecules were developed to be used as mucosal adjuvants [40]. The feasibility of mucosal immunization was first demonstrated in mice immunized orally with bacterial lysates or inactivated whole-cell bacteria together with CT, LT or their non-toxic mutants [35], obtaining a high rate of protection against H. pylori. Presently, the use in humans of whole-cell based vaccines could be hampered by the presence of bacterial components that may induce unwanted responses, as, for instance, antigens that have homology with human ones. In particular, H. pylori expresses Lewis antigens identical to those occurring on the surface of gastric epithelial cells [41] and peptides cross-reactive with human H+, K+-ATPase [19,20]. Thus, the current research on an H. pylori vaccine is focused on recombinant protein antigens. The efficacy of prophylactic and therapeutic immunization against H. pylori has been demonstrated for a variety of native or recombinant antigens, such as urease, heat shock proteins, VacA, CagA, HP-NAP, catalase [35], HpaA (Helicobacter pylori adhesin A) [42] and SOD (superoxide dismutase) [43]. Furthermore, DNA vaccines and different delivery systems, such as live Salmonella or poliovirus vectors, have been used in animals [44]. In most cases partial protection was observed, i.e., gastric colonization was reduced, but not abolished, suggesting that higher efficacy could be achieved by combining more than one antigen. The most relevant non-clinical studies carried out with H. pylori antigens that subsequently were included in vaccines that underwent clinical trials are described in the next section of this review, dedicated to these antigens. Recent studies attempted to identify further protective antigens in mice, such as Hp0410 (neuraminyllactose-binding hemagglutinin HpaA homologue) [45], Tpx (thiol peroxidase) [46], outer membrane proteins [47] and alkyl hydroperoxide reductase [48]. Other studies attempted to use previously known protective antigens in novel forms (e.g., fusion proteins, portions encompassing defined epitopes, constructs epitope-based vaccines), demonstrating either therapeutic or prophylactic efficacy in mice [49–56]. Diseases 2014, 2 190 All of these studies confirmed that protection against H. pylori can be achieved by vaccination in animal models; however, complete protection is rarely achieved, suggesting that the optimization of the antigen combination, adjuvant and route and regimen of immunization is still required. Moreover, efficacy in animals is not necessarily predictive of efficacy in humans; unfortunately, this seems to have
Load more

Recommended publications
  • Salmonella Enterica Subspecies Arizonae Infection of Adult Patients
    Lee et al. BMC Infectious Diseases (2016) 16:746 DOI 10.1186/s12879-016-2083-0 RESEARCHARTICLE Open Access Salmonella enterica subspecies arizonae infection of adult patients in Southern Taiwan: a case series in a non-endemic area and literature review Yi-Chien Lee1, Miao-Chiu Hung2, Sheng-Che Hung3,4, Hung-Ping Wang1, Hui-Ling Cho5, Mei-Chu Lai6 and Jann-Tay Wang7* Abstract Background: The majority of Salmonella arizonae human infections have been reported in southwestern United States, where rattlesnake-based products are commonly used to treat illness; however, little is known in non-endemic areas. We reviewed and analyzed the clinical manifestations and treatment outcomes in adult patients with S. arizonae infection at our institution. Method: A retrospective study was conducted at a regional teaching hospital in southern Taiwan from July 2007 to June 2014. All adult patients diagnosed with S. arizonae infections and treated for at least three days at Chia-Yi Christian Hospital were included. Patients were followed till discharge. Results: A total of 18 patients with S. arizonae infections (median age: 63.5 years) were enrolled for analysis, of whom two thirds were male. The three leading underlying diseases were diabetes mellitus, peptic ulcer disease and malignancy. Ten patients had bacteraemia and the most common infection focus was the lower respiratory tract. Most of the patients (72.2%) received third-generation cephalosporins as definitive therapy. In contrast, ampicillin-based regimens (accounting for 45.2%) were the major treatment modalities in previous reports. The crude in-hospital mortality was 5.6%, which was much lower than what was previously reported (22.7%).
    [Show full text]
  • Dec 2020 Summary Slides
    DEC 2020 DIAGNOSIS LIST 20-1201: syphilitic colitis [large bowel; GI path+ID path] 20-1202: metastatic leiomyosarcoma [lung; GYN pathology] 20-1203: large B-cell lymphoma with IRF4 translocation [LN; hematopath] 20-1204: extranodal NK/T cell lymphoma [testis; hematopath] 20-1205: extranodal marginal zone lymphoma [uterus; hematopath] 20-1206: synovial-like metaplasia [uterus; GYN pathology] 20-1207: Russell body cervicitis [uterus; GYN pathology] Disclosures December 7, 2020 Dr. Ankur Sangoi has disclosed a financial relationship with Google (consultant). South Bay Pathology Society has determined that this relationship is not relevant to the planning of the activity or the clinical cases being presented. The following planners and faculty had no financial relationships with commercial interests to disclose: Presenters: Activity Planners/Moderator: Natalie Patel, MD Kristin Jensen, MD Mahendra Ranchod, MD Megan Troxell, MD, PhD Ashley Volaric, MD Yaso Natkunam, MD, PhD Neslihan Kayraklioglu, MD Robert Ohgami, MD, PhD Josh Menke, MD Charles Lombard, MD 20-1201 scanned slide avail! Natalie Patel; El Camino Hospital 58-year-old M, reported h/o IBD/UC. Recently presented with rectal bleeding, stool cultures negative for C.diff. Patient put back on mesalamine and bleeding improved, however continued to have discomfort. Left colon/rectal biopsy performed, rule out CMV. IHCs • Warthin starry: Negative • CMV: Negative • Treponema pallidum: Positive Treponema pallidum IHC Treponema pallidum immunostain Findings • Colonoscopy: Rectal ulceration • History of colitis for 3 years – diagnosis of ulcerative colitis on mesalamine • History of unprotected sex with men 4 months prior • Tests: • 1. HIV/Hep B/Tb/Gonorrhea/chlamydia: negative • 2. RPR: Reactive (titer: 1:256 ) • 3.
    [Show full text]
  • Phenotypic and Genomic Analyses of Burkholderia Stabilis Clinical Contamination, Switzerland Helena M.B
    RESEARCH Phenotypic and Genomic Analyses of Burkholderia stabilis Clinical Contamination, Switzerland Helena M.B. Seth-Smith, Carlo Casanova, Rami Sommerstein, Dominik M. Meinel,1 Mohamed M.H. Abdelbary,2 Dominique S. Blanc, Sara Droz, Urs Führer, Reto Lienhard, Claudia Lang, Olivier Dubuis, Matthias Schlegel, Andreas Widmer, Peter M. Keller,3 Jonas Marschall, Adrian Egli A recent hospital outbreak related to premoistened gloves pathogens that generally fall within the B. cepacia com- used to wash patients exposed the difficulties of defining plex (Bcc) (1). Burkholderia bacteria have large, flexible, Burkholderia species in clinical settings. The outbreak strain multi-replicon genomes, a large metabolic repertoire, vari- displayed key B. stabilis phenotypes, including the inabil- ous virulence factors, and inherent resistance to many anti- ity to grow at 42°C; we used whole-genome sequencing to microbial drugs (2,3). confirm the pathogen was B. stabilis. The outbreak strain An outbreak of B. stabilis was identified among hos- genome comprises 3 chromosomes and a plasmid, shar- ing an average nucleotide identity of 98.4% with B. stabilis pitalized patients across several cantons in Switzerland ATCC27515 BAA-67, but with 13% novel coding sequenc- during 2015–2016 (4). The bacterium caused bloodstream es. The genome lacks identifiable virulence factors and has infections, noninvasive infections, and wound contamina- no apparent increase in encoded antimicrobial drug resis- tions. The source of the infection was traced to contaminat- tance, few insertion sequences, and few pseudogenes, ed commercially available, premoistened washing gloves suggesting this outbreak was an opportunistic infection by used for bedridden patients. After hospitals discontinued an environmental strain not adapted to human pathogenic- use of these gloves, the outbreak resolved.
    [Show full text]
  • Salmonella Spp. Mehrdad Tajkarimi
    PHR 250, B6 04/04/07 Salmonella spp. Mehrdad Tajkarimi 1 Introduction, history and contemporary problems 1.1 Introduction Infections with Salmonella are a major cause of bacterial foodborne diarrhea in humans worldwide. These bacterial pathogens are crucial zoonotic agents in the veterinary as well as medical field. Sporadic cases of human infections due to contact with household animals shedding Salmonella have repeatedly been reported; however, prevalence of Salmonella spp was 0% for all samples from 94 wild turtles. 1.2 History Water and milk were found to be vehicles of the etiologic agent of enteric fever by epidemiological evidence several years before the agent itself was identified in 1874. The organism, now named Salmonella enterica serotype Typhi, was discovered in 1880. While S. Typhi became an enormous problem in the US in the early industrial era, the disease burden associated with non-typhoid Salmonella was low before World War II. In 1943 in Sweden, it was found that 26% of wild rats were carriers of S. Enteritidis and/or S. Typhimurium. These creatures still seem closely associated with Salmonella also in the US. There are limited historical data on the prevalence of Salmonella in healthy animals, carcasses or meat. Improvements in sanitation nearly eliminated S. Typhi as a cause of indigenous infections in the US and other developed countries. Decades later, non-typhoid Salmonella infections began to increase in importance – a trend that may have peaked near 1990. In 2006, 2496 farm samples were collected quarterly from 18 different farms across five states (Alabama, California, North Carolina, Tennessee, and Washington) over a 24- month period.
    [Show full text]
  • Subtractive Inhibition Assay for the Detection of Campylobacter Jejuni In
    www.nature.com/scientificreports OPEN Subtractive inhibition assay for the detection of Campylobacter jejuni in chicken samples using surface Received: 5 March 2019 Accepted: 13 August 2019 plasmon resonance Published: xx xx xxxx Noor Azlina Masdor1,2, Zeynep Altintas3, Mohd. Yunus Shukor4 & Ibtisam E. Tothill1 In this work, a subtractive inhibition assay (SIA) based on surface plasmon resonance (SPR) for the rapid detection of Campylobacter jejuni was developed. For this, rabbit polyclonal antibody with specifcity to C. jejuni was frst mixed with C. jejuni cells and unbound antibody was subsequently separated using a sequential process of centrifugation and then detected using an immobilized goat anti-rabbit IgG polyclonal antibody on the SPR sensor chip. This SIA-SPR method showed excellent sensitivity for C. jejuni with a limit of detection (LOD) of 131 ± 4 CFU mL−1 and a 95% confdence interval from 122 to 140 CFU mL−1. The method has also high specifcity. The developed method showed low cross- reactivity to bacterial pathogens such as Salmonella enterica serovar Typhimurium (7.8%), Listeria monocytogenes (3.88%) and Escherichia coli (1.56%). The SIA-SPR method together with the culturing (plating) method was able to detect C. jejuni in the real chicken sample at less than 500 CFU mL−1, the minimum infectious dose for C. jejuni while a commercial ELISA kit was unable to detect the bacterium. Since the currently available detection tools rely on culturing methods, which take more than 48 hours to detect the bacterium, the developed method in this work has the potential to be a rapid and sensitive detection method for C.
    [Show full text]
  • A Review of Salmonella Enterica with Particular Focus
    Veterinary World, EISSN: 2231-0916 REVIEW ARTICLE Available at www.veterinaryworld.org/Vol.12/April-2019/5.pdf Open Access A review of Salmonella enterica with particular focus on the pathogenicity and virulence factors, host specificity and antimicrobial resistance including multidrug resistance Saleh Mohammed Jajere Department of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, University of Maiduguri, PMB 1069, Maiduguri, Borno State, Nigeria. Corresponding author: Saleh Mohammed Jajere, e-mail: [email protected] Received: 19-12-2018, Accepted: 11-02-2019, Published online: 06-04-2019 doi: 10.14202/vetworld.2019.504-521 How to cite this article: Jajere SM (2019) A review of Salmonella enterica with particular focus on the pathogenicity and virulence factors, host specificity and antimicrobial resistance including multidrug resistance, Veterinary World, 12(4):504-521. Abstract Salmonella genus represents the most common foodborne pathogens frequently isolated from food-producing animals that is responsible for zoonotic infections in humans and animal species including birds. Thus, Salmonella infections represent a major concern to public health, animals, and food industry worldwide. Salmonella enterica represents the most pathogenic specie and includes > 2600 serovars characterized thus far. Salmonella can be transmitted to humans along the farm-to-fork continuum, commonly through contaminated foods of animal origin, namely poultry and poultry-related products (eggs), pork, fish etc. Some Salmonella
    [Show full text]
  • Salmonella Bongori Provides Insights Into the Evolution of the Salmonellae
    Salmonella bongori Provides Insights into the Evolution of the Salmonellae Maria Fookes1", Gunnar N. Schroeder2", Gemma C. Langridge1", Carlos J. Blondel3, Caterina Mammina4, Thomas R. Connor1, Helena Seth-Smith1, Georgios S. Vernikos1, Keith S. Robinson2, Mandy Sanders1, Nicola K. Petty1, Robert A. Kingsley1, Andreas J. Ba¨umler5, Sean-Paul Nuccio5,Ine´s Contreras3, Carlos A. Santiviago3, Duncan Maskell6, Paul Barrow7, Tom Humphrey8, Antonino Nastasi9, Mark Roberts10, Gad Frankel2, Julian Parkhill1, Gordon Dougan1, Nicholas R. Thomson1* 1 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, 2 Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology, Imperial College London, London, United Kingdom, 3 Departamento de Bioquı´mica y Biologı´a Molecular, Facultad de Ciencias Quı´micas y Farmace´uticas, Universidad de Chile, Santiago, Chile, 4 Dept. Sciences for Health Promotion ‘‘G. D’Alessandro’’, University of Palermo, Palermo, Italy, 5 Department of Medical Microbiology and Immunology, School of Medicine, University of California at Davis, Davis, California, United State of America, 6 Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom, 7 School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington, Leicestershire, United Kingdom, 8 National Centre for Zoonosis Research, University of Liverpool, Leahurst Campus, Neston, Wirral, United Kingdom, 9 Dipartimento di Sanita` Publica, Universita` di Firenze, Italy, 10 Institute of Comparative Medicine, Faculty of Veterinary Medicine, University of Glasgow, Glasgow, United Kingdom Abstract The genus Salmonella contains two species, S. bongori and S. enterica. Compared to the well-studied S. enterica there is a marked lack of information regarding the genetic makeup and diversity of S.
    [Show full text]
  • Marginal Zone Lymphoma
    311 Original Article Marginal Zone Lymphoma Omid S. Shaye, MD, and Alexandra M. Levine, MD, Los Angeles, California Key Words common of the 3 subtypes is extranodal MZL of MALT Marginal zone lymphoma, MALT lymphoma, splenic marginal zone type, which represents 8% of non-Hodgkin lymphomas.3 lymphoma, nodal marginal zone lymphoma Gastric MALT lymphoma (GML) is the prototype of this entity, with considerable data describing its association Abstract with chronic gastritis secondary to Helicobacter pylori. Marginal zone lymphomas (MZLs) comprise 3 distinct entities: extra- The other MZL subtypes are less common, with SMZL and nodal MZL of mucosa-associated lymphoid tissue (MALT), splenic MZL, and nodal MZL. Gastric MALT lymphoma is the most common NMZL each composing less than 1% of all lymphomas. extranodal MZL and often develops as a result of chronic Helicobacter pylori gastritis. Such cases frequently respond to antibiotics directed against H. pylori. Antigen-driven lymphomatous disease can also be Extranodal MZL of MALT Type seen in the association of Borrelia burgdorferi with MALT lymphoma Isaacson and Wright4 first described MALT lymphoma of the skin, Chlamydia psittaci with MALT lymphoma of the ocular adnexa, Campylobacter jejuni with immunoproliferative disease of in 1983. Since then, the unique pathogenesis of disease, the small intestine, and hepatitis C with splenic MZL. This article dis- which is related to antigen-induced proliferation of lym- cusses the pathogenesis and clinical features of MZL and the treat- phoid tissue, has received increasing attention. MALT ment options available to patients. (JNCCN 2006;4:311–318) can be found in 2 situations. The usual and normal form consists of lymphoid tissue present in specific areas in the In 1994, the Revised European-American Lymphoma gut, such as Peyer patches.
    [Show full text]
  • Influence of Bacterial Competitors on Salmonella Enterica And
    foods Article Influence of Bacterial Competitors on Salmonella enterica and Enterohemorrhagic Escherichia coli Growth in Microbiological Media and Attachment to Vegetable Seeds Da Liu 1, Ronald Walcott 2, Kevin Mis Solval 1 and Jinru Chen 1,* 1 Department of Food Science and Technology, The University of Georgia, Griffin, GA 30602, USA; [email protected] (D.L.); [email protected] (K.M.S.) 2 Department of Plant Pathology, The University of Georgia, Athens, GA 30602, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-770-412-4738 Abstract: Interests in using biological agents for control of human pathogens on vegetable seeds are rising. This study evaluated whether probiotic bacterium Lactobacillus rhamnosus GG, bacterial strains previously used as biocontrol agents in plant science, as well as a selected plant pathogen could compete with foodborne human pathogens, such as Salmonella enterica and enterohemorrhagic Escherichia coli (EHEC), for growth in microbiological media and attachment to vegetable seeds; and to determine whether the metabolites in cell-free supernatants of competitive bacterial spent cultures could inhibit the growth of the two pathogens. The results suggest that the co-presence of competitive bacteria, especially L. rhamnosus GG, significantly (p < 0.05) inhibited the growth of Salmonella and EHEC. Cell-free supernatants of L. rhamnosus GG cultures significantly reduced the pathogen populations in microbiological media. Although not as effective as L. rhamnosus GG in inhibiting the growth of Salmonella and EHEC, the biocontrol agents were more effective in competing for attachment to vegetable seeds. The study observed the inhibition of human bacterial pathogens Citation: Liu, D.; Walcott, R.; Mis by competitive bacteria or their metabolites and the competitive attachment to sprout seeds among Solval, K.; Chen, J.
    [Show full text]
  • Relevance of Helicobacter Pylori Virulence Factors for Vaccine Development
    Relevance of H. pylori virulence factors ARTÍCULO DE REVISIÓN Relevance of Helicobacter pylori virulence factors for vaccine development Luz del Carmen Hernández-Hernández, MS,(1) Eduardo César Lazcano-Ponce, PhD,(2) Yolanda López-Vidal, PhD,(3) Germán Rubén Aguilar-Gutiérrez, PhD(1) Hernández-Hernández LC, Lazcano-Ponce EC, Hernández-Hernández LC, Lazcano-Ponce EC, López-Vidal Y, Aguilar-Gutiérrez GR. López-Vidal Y, Aguilar-Gutiérrez GR. Relevance of Helicobacter pylori virulence Relevancia de los factores de virulencia factors for vaccine development. de Helicobacter pylori para el desarrollo de vacunas. Salud Publica Mex 2009;51 suppl 3:S447-S454. Salud Publica Mex 2009;51 supl 3:S447-S454. Abstract Resumen Helicobacter pylori infection increases the risk for a wide spec- La infección por Helicobacter pylori incrementa el riesgo de trum of clinical outcomes, ranging from peptic ulcer disease un amplio espectro de cuadros clínicos, que van de la úlcera to gastric cancer. However, the infection induces gastric and péptica al cáncer gástrico. Sin embargo, la infección sólo duodenal ulceration or gastric cancer in only a minority of in- induce ulceración gástrica y duodenal o cáncer gástrico en fected subjects because H. pylori strains are genetically diverse la minoría de los sujetos infectados debido que las cepas de and express different virulence factors. Individuals infected H. pylori son genéticamente diversas y expresan diferentes with strains that express these virulence factors probably factores de virulencia. Así, los individuos infectados por cepas develop severe diseases such as gastric cancer. Nevertheless, que expresan estos factores de virulencia probablemente the ancient relationship between H. pylori and humans sug- desarrollan enfermedades severas como el cáncer gástrico.
    [Show full text]
  • Molecular Typing and Evolutionary Relationships of Salmonella Enterica Serovar Typhi
    Molecular typing and evolutionary relationships of Salmonella enterica serovar Typhi Sophie Octavia School of Biotechnology and Biomolecular Sciences The University of New South Wales Australia A thesis submitted for the degree of Doctor of Philosophy March 2008 PLEASE TYPE 1.3.1 THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: Octavia First name: Sophie Other name/s: PhD in Microbiology Abbreviation for degree as given in the University calendar: School: Biotechnology and Biomolecular Sciences Faculty: Science Title: Molecular typing and evolutionary relationships of Salmonella enterica serovar Typhi Abstract 350 words maximum: (PLEASE TYPE) The evolutionary relationship between Salmonella enterica serovar Typhi, other typhoid-like enteric fever causing serovars and 10 non- Typhoid serovars from S. enterica subspecies I, could not be determined by comparative nucleotide sequences of six genes. Phylogenetic analyses of the dataset showed that the genes of interest underwent frequent recombination, suggesting a low level of clonality within subspecies I of S. enterica. To establish the evolutionary relationships within serovar Typhi, genome-wide Single Nucleotide Polymorphism (SNP) was explored as a marker for both typing purposes and phylogenetic analysis. Thirty eight SNPs were typed in 73 global Typhi isolates, including 18 isolates expressing the special flagellar antigen z66, using restriction enzyme digestion method. The isolates were differentiated into 23 SNP profiles and grouped into four distinct clusters. The z66 isolates were divided into four SNP profiles and were all grouped into one cluster, suggesting a single origin. An alternative SNP typing method using the hairpin real time PCR assay was investigated to type four additional SNPs, termed as biallelic polymorphisms (BiP).
    [Show full text]
  • The Impact of Neutrophils on the Sensitivity of Lymphoma B Cells to Cancer Therapy Taghreed Hirz
    Polymorphonuclear neutrophils and cancer : the impact of neutrophils on the sensitivity of lymphoma B cells to cancer therapy Taghreed Hirz To cite this version: Taghreed Hirz. Polymorphonuclear neutrophils and cancer : the impact of neutrophils on the sensi- tivity of lymphoma B cells to cancer therapy. Cancer. Université Claude Bernard - Lyon I, 2015. English. NNT : 2015LYO10327. tel-01417800 HAL Id: tel-01417800 https://tel.archives-ouvertes.fr/tel-01417800 Submitted on 16 Dec 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. No d’ordre 327-2015 Année 2015 THESE DE L’UNIVERSITE DE LYON Délivrée par L’UNIVERSITE CLAUDE BERNARD LYON I ECOLE DOCTORALE BIOLOGIE MOLECULAIRE, INTEGRATIVE ET CELLULAIRE DIPLOME DE DOCTORAT (arrêté du 7 août 2006) soutenue publiquement le 14 Décembre 2015 par HIRZ Taghreed TITRE Neutrophiles polymorphonucléaires et cancer: L'impact des neutrophiles sur la sensibilité des cellules de lymphome B aux thérapies anti-cancéreuses Directeur de thèse : DUMONTET Charles Jury: Mme. Catherine THIEBLEMONT, Professeure, Paris, France M. Christophe CAUX, Directeur de Recherche, Université Lyon 1, France M. Charles DUMONTET, Professeur, Université Lyon 1, France M. Sebastien JAILLON, Directeur de Recherche, Milan, I UNIVERSITE CLAUDE BERNARD - LYON 1 Président de l’Université M.
    [Show full text]